Telomerized presenescent osteoblasts prevent bone mass loss in vivo.
Previously, we showed that human osteoblasts expressing the human telomerase reverse transcriptase (hTERT) gene exhibited specific survival advantages--the result of breaching the replicative senescence barrier and maintaining the phenotypic and functional properties of primary osteoblasts in vitro over the total replicative capacity of primary osteoblasts. We postulated that rejuvenated osteoblasts may have a potential to correct bone loss or osteopenia in age-related osteoporotic diseases. In the present study, we studied whether telomerized presenescent osteoblasts prevent bone mass loss in vivo. After obtaining the informed consent from a patient with osteoarthritis who underwent the arthroplastic knee surgery, osteoblastic cells were isolated from donor bone sample. We transfected the gene encoding hTERT into human osteoblastic cells. Human bone fragments from a donor were incubated with human hTERT-transfected presenescent (in vitro aged) osteoblasts or mock-transfected presenescent osteoblasts in culture medium containing Matrigel. We subcutaneously implanted human bone fragments with telomerized presenescent osteoblasts or primary presenescent osteoblasts as three-dimensional Matrigel xenografts in severe combined immunodeficiency (SCID) mice (each group: six mice) and analyzed the grafts at 6 weeks after implantation. We also determined whether telomerized osteoblasts affect the bone-forming capacity in vivo, using a well-established mouse transplantation model in which ceramic hydroxyapatite/tricalcium phosphate particles are used as carrier vehicle. Telomerized presenescent osteoblasts were rejuvenated, and maintained the functional properties of young osteoblasts in vitro. Bone mineral content (BMC) and bone mineral density (BMD) were measured by ash weight and dual-energy X-ray absorptiometry, respectively. Whereas BMC and BMD of human bone fragments, which were inoculated with aged osteoblasts in SCID mice, decreased with time, telomerized presenescent osteoblasts maintained the BMC and BMD of human bone fragments, indicating that telomerized and rejuvenated osteoblasts may be functional to prevent bone mass loss in vivo. In xenogenic transplants, telomerized osteoblasts generated more bone tissue with lamellar bone structure and cellular components, than did control osteoblasts. These findings suggest that telomerized/rejuvenated presenescent osteoblasts may be used in the development of tissue engineering or cell-based therapy for bone regeneration and repair.
Yudoh
K
K
Department of Bioregulation, Institute of Medical Science, St. Marianna University, Miyamae-ku, Kawasaki City, Japan.
Nishioka
K
K
D000818:Animals; D015519:Bone Density; D001861:Bone Regeneration / Q000235:genetics*; D002470:Cell Survival; D016922:Cellular Senescence; D004268:DNA-Binding Proteins; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D010006:Osteoblasts / Q000637:transplantation / Q000648:ultrastructure*; D010024:Osteoporosis / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D019098:Telomerase / Q000032:analysis / Q000235:genetics; D016615:Telomere / Q000637:transplantation* / Q000648:ultrastructure; D014183:Transplantation, Heterologous
D004268:DNA-Binding Proteins; D019098:Telomerase